Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06008457 · ClinicalTrials.gov registry record
Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit
A clinical trial, sponsored by Sequenom.
- Completed
- Registry status
- 1,600
- Enrollment target
NCT06008457: Completed study, sponsored by Sequenom.
NCT06008457 is a clinical trial that has completed, run by Sequenom. The registered enrollment target is 1,600 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06008457 has completed, sponsored by Sequenom.
- COMPLETED
- Registry status
- 1,600 participants
- Enrollment target
Study Summary
To compare the results obtained by analysis of a self-collected anterior nasal (AN) swab as part of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit to a healthcare provider (HCP)-collected AN swab in patients with symptoms of viral respiratory infection consistent with influenza A (Flu A), influenza B (Flu B), respiratory syncytial virus (RSV) and/or SARS-CoV-2 (C-19).
Primary Outcome
To evaluate the concordance between the results of a self-collected AN swab specimen using the Labcorp COVID-19+Flu+RSV Test Home Collection Kit as analyzed by the Labcorp Seasonal Respiratory Virus RT-PCR Test and an HCP-collected AN swab as analyzed by the comparator assays in subjects presenting with symptoms of viral respiratory infection consistent with Flu A, Flu B, RSV and/or C-19.
Interventions
- DEVICE Labcorp COVID-19+Flu+RSV Test Home Collection Kit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,600 participants |
| Start Date | 2023-04-17 |
| Est. Completion | 2025-05-31 |
What the finished NCT06008457 record still lists
NCT06008457 is an observational study that tracks outcomes without assigning an intervention. Its 1,600 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Labcorp COVID-19+Flu+RSV Test Home Collection Kit is the first listed.
NCT06008457 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06008457 about?
NCT06008457 is a clinical study titled "Evaluation of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit". To compare the results obtained by analysis of a self-collected anterior nasal (AN) swab as part of the Labcorp COVID-19+Flu+RSV Test Home Collection Kit to a healthcare provider (HCP)-collected AN swab in patients with symptoms of viral respiratory infection consistent with influenza A (Flu A), inf...
What is the current status of trial NCT06008457?
This trial is currently completed. The enrollment target is 1,600 participants. The study started on 2023-04-17. Estimated completion is 2025-05-31.
What interventions are being tested in trial NCT06008457?
The interventions under investigation include: Labcorp COVID-19+Flu+RSV Test Home Collection Kit (DEVICE).
Who is sponsoring clinical trial NCT06008457?
This trial is sponsored by Sequenom, which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
- NCT04314401 · 1,600 participants
National Cancer Institute "Cancer Moonshot Biobank"
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI